LON:HIK Hikma Pharmaceuticals (HIK) Share Price, News & Analysis GBX 1,896 +34.00 (+1.83%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 1,854.46▼ 1,89650-Day Range 1,809▼ 2,01052-Week Range 1,711▼ 2,222Volume208,865 shsAverage Volume377,970 shsMarket Capitalization£4.21 billionP/E Ratio2,829.85Dividend Yield3.01%Price TargetGBX 2,225 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Get Hikma Pharmaceuticals alerts: Email Address Hikma Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside17.4% UpsideGBX 2,225 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-2.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares£1.46 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 stars 2.3 Analyst's Opinion Consensus RatingHikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageHikma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Hikma Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HIK. Previous Next 0.8 Dividend Strength Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 2.93%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Hikma Pharmaceuticals' dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Hikma Pharmaceuticals is -2.61. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for HIK on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought £14,565.44 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders30.62% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.63% of the stock of Hikma Pharmaceuticals is held by institutions.Read more about Hikma Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 2,813.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 140.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 2,813.79, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 150.64.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Hikma Pharmaceuticals Stock (LON:HIK)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More HIK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIK Stock News HeadlinesMay 17, 2024 | finanznachrichten.deActive Pharmaceutical Ingredient Market Worth $238.3 billion | MarketsandMarketsApril 26, 2024 | markets.businessinsider.comEuropean Stocks Close On Strong Note As Investors Cheer Earnings UpdatesJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.April 25, 2024 | thetimes.co.ukThe drugs do work as AstraZeneca leads the packApril 25, 2024 | msn.comHikma: Pharma giant starts year strong as new product sales surge in key marketsApril 25, 2024 | lse.co.ukHikma Pharmaceuticals backs outlook after making strong start to 2024April 24, 2024 | msn.comIs this FTSE growth superstar set to soar even higher on new drug results?April 17, 2024 | msn.comCarisma Therapeutics (CARM) Price Target Decreased by 10.00% to 9.18July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.April 14, 2024 | seekingalpha.comHKMPY Hikma Pharmaceuticals PLCApril 11, 2024 | markets.businessinsider.comEuropean Stocks Close Lower Amid Uncertainty About Interest RatesApril 11, 2024 | uk.finance.yahoo.comI’m considering these 3 undervalued pharma stocks to buy for my portfolio in AprilApril 7, 2024 | finance.yahoo.comGeneric Medicine Market To Reach USD 818.3 Billion By 2032, Says DataHorizzon ResearchApril 3, 2024 | msn.comFTSE 100 Live: Index slips after topping 8000 and nearing record high, Superdry plungesMarch 22, 2024 | finance.yahoo.comGlobal Lidocaine Hydrochloride Market Report 2024, by Dosage Form, Application, Distribution Channel and RegionMarch 21, 2024 | finance.yahoo.comLidocaine Hydrochloride Market Forecasted to Reach USD 1.56 Billion by 2034 with Robust Growth in Asia Pacific RegionMarch 17, 2024 | msn.comBig pharma shakeup in Morocco as Sanofi sells business to HikmaMarch 15, 2024 | finanznachrichten.deHyloris Pharmaceuticals SA: Hyloris Reports Full Year Results for 2023 & Provides Business OutlookSee More Headlines Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 5/3 Dividend3/21/2024Dividend Payable5/03/2024Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees9,100Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,225 High Stock Price TargetGBX 2,750 Low Stock Price TargetGBX 2,000 Potential Upside/Downside+18.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.67 Trailing P/E Ratio2,813.79 Forward P/E Ratio11.89 P/E Growth2.38Net Income£190 million Net Margins6.61% Pretax MarginN/A Return on Equity8.81% Return on Assets8.46% Debt Debt-to-Equity Ratio53.92 Current Ratio1.57 Quick Ratio1.27 Sales & Book Value Annual Sales£2.88 billion Price / Sales1.45 Cash FlowGBX 226.08 per share Price / Cash Flow8.34 Book ValueGBX 994 per share Price / Book1.90Miscellaneous Outstanding Shares221,880,000Free FloatN/AMarket Cap£4.18 billion OptionableNot Optionable Beta0.44 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.21MMr. Riad Ali Mishlawi (Age 60)CEO & Director Comp: $869.23kMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $1.81MMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Patricia BousfieldChief Information OfficerMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGeneral CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive Vice President of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsMore ExecutivesKey CompetitorsHUTCHMEDLON:HCMIndiviorLON:INDVAmryt PharmaLON:AMYTBenchmarkLON:BMKAllergy TherapeuticsLON:AGYView All CompetitorsInsidersRiad MishlawiBought 736 shares on 5/7/2024Total: £1.46 M ($1,979.00/share)View All Insider Transactions HIK Stock Analysis - Frequently Asked Questions How have HIK shares performed this year? Hikma Pharmaceuticals' stock was trading at GBX 1,789 on January 1st, 2024. Since then, HIK shares have increased by 6.0% and is now trading at GBX 1,896. View the best growth stocks for 2024 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH). This page (LON:HIK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
